Medications for Parkinson’s Disease

Parkinson’s disease is a progressive neurodegenerative disorder that affects movement. The main symptoms are bradykinesia (slowness of movement), rigidity, and resting tremor. The disease is caused by a decrease in dopamine production in the basal ganglia of the brain.

There are several medications used to treat Parkinson’s disease. L-dopa is an amino acid precursor of dopamine that can cross the blood-brain barrier and replenish depleted dopamine levels. It is given with a dopa decarboxylase inhibitor to limit side effects. Entacapone is a COMT inhibitor that prolongs the duration of L-dopa and smooths out fluctuations in plasma concentration.

Selegiline is a monoamine oxidase B inhibitor that reduces dopamine metabolism in the brain and potentiates the action of L-dopa. It is effective early and late in the disease but can cause cognitive side effects due to its metabolization to amphetamine.

Benzatropine is a muscarinic antagonist that can be useful in managing resting tremor. Bromocriptine is a dopamine agonist that can be used alone or in combination with L-dopa.

Overall, these medications aim to increase dopamine levels in the brain and improve movement symptoms in Parkinson’s disease.

Retinal detachment and vitreous haemorrhage are the two main causes of sight loss in proliferative diabetic retinopathy.

Understanding Diabetic Retinopathy

Diabetic retinopathy is a leading cause of blindness among adults aged 35-65 years old. The condition is caused by hyperglycemia, which leads to abnormal metabolism in the retinal vessel walls and damage to endothelial cells and pericytes. This damage causes increased vascular permeability, resulting in exudates seen on fundoscopy. Pericyte dysfunction predisposes to the formation of microaneurysms, while neovascularization is caused by the production of growth factors in response to retinal ischemia.

Patients with diabetic retinopathy are classified into those with nonproliferative diabetic retinopathy (NPDR), proliferative retinopathy (PDR), and maculopathy. NPDR is further classified into mild, moderate, and severe, depending on the presence of microaneurysms, blot hemorrhages, hard exudates, cotton wool spots, venous beading/looping, and intraretinal microvascular abnormalities. PDR is characterized by retinal neovascularization, which may lead to vitreous hemorrhage, and fibrous tissue forming anterior to the retinal disc. Maculopathy is based on location rather than severity and is more common in Type II DM.

Management of diabetic retinopathy involves optimizing glycaemic control, blood pressure, and hyperlipidemia, as well as regular review by ophthalmology. Treatment options include intravitreal vascular endothelial growth factor (VEGF) inhibitors for maculopathy, regular observation for nonproliferative retinopathy, and panretinal laser photocoagulation and intravitreal VEGF inhibitors for proliferative retinopathy. Vitreoretinal surgery may be necessary in cases of severe or vitreous hemorrhage.

Myths about Hospice Care: Debunked

Hospice care is often misunderstood, leading to misconceptions about who can receive it and what it entails. Here are some common myths about hospice care debunked:

Myth #1: Hospice care is only for patients with terminal cancer.
Fact: Patients with any terminal diagnosis can seek hospice care, not just those with cancer. Commonly, patients with chronic lung disease, dementia, and neurodegenerative disorders benefit from hospice care.

Myth #2: Patients must be bed-bound to receive hospice care.
Fact: Mobility status does not affect admission to hospice. Patients in hospices often take part in activities and may be fully mobile.

Myth #3: Patients must have a ‘do not resuscitate’ (DNACPR) decision to receive hospice care.
Fact: Although most patients will have a DNACPR decision in a hospice, this is not a requirement.

Myth #4: Patients must have uncontrolled pain to receive hospice care.
Fact: While some patients may be admitted to a hospice for pain control, hospices are able to treat other symptoms, and pain control can be addressed in other settings, depending on the patient’s needs and wishes.

Hospice care and palliative care both focus on quality of life care for the patient and address adjustment to illness and end-of-life issues. Both forms of care address pain and symptom control issues for patients. However, hospice care is for patients who are no longer actively seeking curative treatment and have a terminal diagnosis with a life expectancy of 6 months or less. In contrast, for palliative care treatment, patients may still be undergoing aggressive treatment and do not have to be terminally ill. It is important to understand the facts about hospice care to make informed decisions about end-of-life care.

Measles and its Complications

Measles is a highly contagious viral illness caused by an RNA paramyxovirus. Patients usually experience non-specific cold-like symptoms such as cough, fever, coryza, and conjunctivitis for a week before the appearance of a rash. Koplik spots, grey/white spots in the oral mucous membranes, are a telltale sign of the disease. Treatment is supportive, and symptoms usually resolve within one to two weeks in mild cases.

However, measles can lead to various complications, including diarrhea, vomiting, conjunctivitis, and laryngitis. Less common complications include meningitis, pneumonia, encephalitis, hepatitis, bronchitis, thrombocytopenia, and croup. Rare complications such as optic neuritis and subacute sclerosing panencephalitis (SSPE) can also occur. SSPE is a fatal condition that can develop several years after the measles infection and is characterized by gradual psycho-neurological deterioration, seizures, ataxia, and coma. Fortunately, SSPE is rare, occurring in only 1 in 100,000 cases of measles.

Differential diagnosis of obstructive liver function tests

Obstructive liver function tests, characterized by elevated conjugated bilirubin and alkaline phosphatase, can be caused by various conditions. Here are some possible differential diagnoses:

– Stone in common bile duct: This can obstruct the flow of bile and cause jaundice, as well as dilate the bile duct. The absence of urobilinogen in urine and the correction of prothrombin time with vitamin K support the diagnosis.
– Haemolytic anaemia: This can lead to increased breakdown of red blood cells and elevated unconjugated bilirubin, but usually does not affect alkaline phosphatase.
– Hepatitis: This can cause inflammation of the liver and elevated transaminases, but usually does not affect conjugated bilirubin or alkaline phosphatase.
– Liver cirrhosis: This can result from chronic liver damage and fibrosis, but usually does not cause obstructive liver function tests unless there is associated biliary obstruction or cholestasis.
– Paracetamol overdose: This can cause liver damage and elevated transaminases, but usually does not affect conjugated bilirubin or alkaline phosphatase unless there is associated liver failure or cholestasis.

Therefore, a careful clinical evaluation and additional tests may be needed to confirm the underlying cause of obstructive liver function tests and guide appropriate management.

Antipsychotics have been found to cause metabolic side effects such as dysglycaemia, dyslipidaemia, and diabetes mellitus. Olanzapine, along with other antipsychotics, is known to primarily cause hyperlipidemia, hypercholesterolemia, hyperglycemia, and weight gain. These drugs act as dopamine antagonists, leading to hyperprolactinemia as dopamine is a prolactin antagonist. However, they do not have any impact on parathyroid hormones or electrolytes.

Antipsychotics are a group of drugs used to treat schizophrenia, psychosis, mania, and agitation. They are divided into two categories: typical and atypical antipsychotics. The latter were developed to address the extrapyramidal side-effects associated with the first generation of typical antipsychotics. Typical antipsychotics work by blocking dopaminergic transmission in the mesolimbic pathways through dopamine D2 receptor antagonism. They are associated with extrapyramidal side-effects and hyperprolactinaemia, which are less common with atypical antipsychotics.

Extrapyramidal side-effects (EPSEs) are common with typical antipsychotics and include Parkinsonism, acute dystonia, sustained muscle contraction, akathisia, and tardive dyskinesia. The latter is a late onset of choreoathetoid movements that may be irreversible and occur in 40% of patients. The Medicines and Healthcare products Regulatory Agency has issued specific warnings when antipsychotics are used in elderly patients, including an increased risk of stroke and venous thromboembolism. Other side-effects include antimuscarinic effects, sedation, weight gain, raised prolactin, impaired glucose tolerance, neuroleptic malignant syndrome, reduced seizure threshold, and prolonged QT interval.

The patient is experiencing difficulty initiating abduction of their affected arm, but is able to actively complete the range of motion if the initial stages of abduction are performed for them. This is consistent with a tear in the supraspinatus muscle, which is the most commonly injured muscle in the rotator cuff. The supraspinatus is responsible for the initial 15 degrees of abduction, after which the deltoid muscle takes over. In contrast, damage to the infraspinatus or teres minor muscles would typically affect lateral rotation or adduction, respectively. A tear in the subscapularis muscle, which is responsible for adduction and medial rotation, is a possible diagnosis given the patient’s symptoms. Dysfunction in the deltoid muscle or axillary nerve would prevent full abduction of the arm, but this is not the case for this patient. Deltoid tears are rare and usually associated with traumatic shoulder dislocation or large rotator cuff injuries.

Valsartan and its Mechanism of Action

Valsartan is a medication that works by blocking the angiotensin-II type 1 (AT1) receptor, which is responsible for regulating blood pressure. This medication has a much greater affinity for the AT1 receptor than the AT2 receptor, making it a potent antagonist of the AT1 receptor. By blocking this receptor, valsartan prevents the increase in angiotensin II levels that can lead to increased stimulation of the AT2 receptor. Unlike ACE inhibitors, valsartan does not reduce angiotensin II production or affect substance P or bradykinin, resulting in a significantly lower incidence of cough. Valsartan is primarily excreted through the biliary tract in feces, with only about 13% being recovered in the urine. Its half-life is approximately six hours, and no dose adjustment is required for patients with a creatinine clearance of 10 ml/min or more.

Screening Tests for Cushing’s Syndrome

Cushing’s syndrome is a condition caused by excessive levels of cortisol in the body. To diagnose this condition, appropriate screening tests are necessary. The preferred test is the 1 mg overnight dexamethasone suppression test, where 1 mg of dexamethasone is given at 11 pm, and cortisol levels are measured at 9 am the following morning. A cortisol concentration less than 50 nmol/L after this test is considered normal.

Another effective test is a 24-hour urine collection to measure free cortisol in the urine. An elevated cortisol level, usually above 250 nmol/day, indicates Cushing’s syndrome. However, random cortisol or 9 am cortisol tests do not provide any diagnostic information.

In investigating the possible cause of Cushing’s syndrome, chest x-rays and adrenal CT scans are useful. These tests can help identify the underlying cause of the condition. It is important to perform appropriate screening tests to diagnose Cushing’s syndrome and determine the best course of treatment.

The most likely cause of the woman’s presentation, who is suspected to have schizophrenia and has been sitting in an uncomfortable position for the last 2 hours, is catatonia. Catatonia is a condition where voluntary movement is stopped or the person stays in an unusual position. It is believed to occur due to abnormalities in the balance of neurotransmitter systems, particularly dopamine, and is commonly associated with certain types of schizophrenia. Treatment for catatonia includes benzodiazepines and electroconvulsive therapy.

Extrapyramidal side effects, neuroleptic malignant syndrome, and serotonin syndrome are not the correct answers for this scenario. Extrapyramidal side effects can occur with antipsychotic medications but would not present with the withdrawn status described. Neuroleptic malignant syndrome is a life-threatening reaction to antipsychotic medications and presents with different symptoms than catatonia. Serotonin syndrome is caused by excess serotonin in the body and is not associated with the patient’s medication or presentation.

Schizophrenia is a mental disorder that is characterized by various symptoms. Schneider’s first rank symptoms are divided into four categories: auditory hallucinations, thought disorders, passivity phenomena, and delusional perceptions. Auditory hallucinations can include hearing two or more voices discussing the patient in the third person, thought echo, or voices commenting on the patient’s behavior. Thought disorders can involve thought insertion, thought withdrawal, or thought broadcasting. Passivity phenomena can include bodily sensations being controlled by external influence or actions/impulses/feelings that are imposed on the individual or influenced by others. Delusional perceptions involve a two-stage process where a normal object is perceived, and then there is a sudden intense delusional insight into the object’s meaning for the patient.

Other features of schizophrenia include impaired insight, incongruity/blunting of affect (inappropriate emotion for circumstances), decreased speech, neologisms (made-up words), catatonia, and negative symptoms such as incongruity/blunting of affect, anhedonia (inability to derive pleasure), alogia (poverty of speech), and avolition (poor motivation). It is important to note that schizophrenia can manifest differently in each individual, and not all symptoms may be present.